Prognostic factors for breast recurrence after conservative breast surgery and radiotherapy: results from a randomised trial

Magee, Brian; Swindell, Ric; Harris, Martin; Banerjee, Shiladitya

doi:10.1016/0167-8140(96)01747-1

Cited by 144 publications

(63 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Breast-conserving surgery plus radiotherapy has been evaluated in five randomized trials (16, 20 Á/24). Whether the target volume for optimal radiotherapy should be wide or limited field has been the subject for one randomized study (25). The majority of these trials are large and conclusive.…”

Section: Radiotherapy In Breast-conservation Surgerymentioning

confidence: 99%

A Systematic Overview of Radiation Therapy Effects in Breast Cancer

Rutqvist¹,

Rose²,

Cavallin‐Ståhl³

2003

Acta Oncologica

View full text Add to dashboard Cite

Section: Radiotherapy In Breast-conservation Surgerymentioning

confidence: 99%

A Systematic Overview of Radiation Therapy Effects in Breast Cancer

Rutqvist¹,

Rose²,

Cavallin‐Ståhl³

2003

Acta Oncologica

View full text Add to dashboard Cite

“…Clinical reports from various centres have shown almost equivalent results between short and standard RT schedules [9][10][11][18][19][20][21][22][23][24][25][26][27] , and it would be interesting to have an overview of the current situation in this field.…”

Section: Review Of Clinical Studiesmentioning

confidence: 99%

Hypofractionated radiotherapy in the treatment of early breast cancer

Plataniotis

2010

WJR

View full text Add to dashboard Cite

Radiotherapy (RT) after tumorectomy in early breast cancer patients is an established treatment modality which conventionally takes 6-7 wk to complete. Shorter RT schedules have been tested in large multicentre randomized trials and have shown equivalent results to that of standard RT (50 Gy in 25 fractions) in terms of local tumor control, patient survival and late post-radiation effects. Some of those trials have now completed 10 years of follow-up with encouraging results for treatments of 3-4 wk and a total RT dose to the breast of 40-42.5 Gy with or without boost. A reduction of 50% in treatment time makes those RT schedules attractive for both patients and health care providers and would have a significant impact on daily RT practice around the world, as it would accelerate patient turnover and save health care resources. However, in hypofractionated RT, a higher (than the conventional 1.8-2 Gy) dose per fraction is given and should be managed with caution as it could result in a higher rate of late postradiation effects in breast, heart, lungs and the brachial plexus. It is therefore advisable that both possible dose inhomogeneity and normal tissue protection should be taken into account and the appropriate technology such as three-dimensional/intensity modulated radiation therapy employed in clinical practice, when hypofractionation is used.

show abstract

“…On the basis of these findings, irradiation of the tumor bed alone was tested in several studies during the 1990s [9][10][11][12][13][14][15][16][17][18][19][20]. In two earlier trials with unselected patients, there was a significant superiority in local control for whole breast radiotherapy (WBRT) compared with partial breast irradiation [10,12]. Interim results of other prospective phase I-II studies, using interstitial implants for carefully selected patients, appear promising [9,11,[13][14][15][17][18][19][20].…”

mentioning

confidence: 99%